Escitalopram in the treatment of anxiety symptoms associated with depression
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Most patients with depression have symptoms of anxiety associated with their illness. Our aim in this study was to investigate the efficacy of escitalopram, a proven antidepressant, on symptoms of anxiety in patients with major depressive disorder (MDD). Data from five placebo-controlled escitalopram studies in MDD were analyzed. Three of the studies also included a comparison with citalopram. In all studies, anxiety was assessed using the Inner Tension item (item 3) of the Montgomery-Asberg Depression Rating Scale (MADRS). In three studies, anxiety symptoms were also specifically assessed, either continuously over time or at baseline and end point, by using the Hamilton Rating Scale for Anxiety (HAM-A), the Anxious Mood item of the HAM-A (item 1), the Psychic Anxiety subscale of the HAM-A (items 1-6 and 14), the Anxiety Psychic item (item 10) of the Hamilton Rating Scale for Depression (HAM-D-24), and the Anxiety/Somatization subfactor (items 10-13, 15, and 17) of the HAM-D-24. Escitalopram was significantly superior to placebo in all comparisons. Citalopram was also consistently better than placebo in all comparisons, except in the HAM-D-24 Anxiety/Somatization subfactor. In some comparisons with placebo, escitalopram showed a significantly earlier onset of action or an earlier separation. Escitalopram was significantly more effective compared to placebo in treating both anxiety symptoms and the entire depression in the total depressive population, as well as in depressive patients with a high degree of anxiety.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
DSM-III-R Generalized Anxiety Disorder in the National Comorbidity Survey
Wittchen, H.-U. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950050015002 · Cited by 967 · cited 3×
“Epidemiological studies have long noted the frequent comorbidity of depression and anxiety; more than half of those diagnosed with a depressive disorder have an anxiety disorder, and anxiety disorders tend to precede depression by several years [Wittchen et al., 1994].”
Roy-Byrne, P. P., Stang, P., Wittchen, H.-U., Ustun, B., Walters, E. E., & Kessler, R. C. (2000) · British Journal of Psychiatry · doi:10.1192/bjp.176.3.229 · Cited by 446 · cited 2×
“…of Psychiatry and Psychotherapy, University of Göttingen, Göttingen, Germany 2H. Lundbeck A/S, Copenhagen, Denmark r 2006 Wiley-Liss, Inc. Fawcett, 1992; Grunhaus et al., 1988; Kessler et al., 1996; Roy-Byrne et al., 2000; van Valkenburg et al., 1984; Vollrath and Angst, 1989].”
Treatment outcomes for primary care patients with major depression and lifetime anxiety disorders.
(1996) · American Journal of Psychiatry · doi:10.1176/ajp.153.10.1293 · Cited by 312 · cited 3×
“It has been shown that the presence of comorbid symptoms confers a less favorable prognosis and poorer outcomes, and that these patients express higher levels of social distress, have higher suicide rates, have increased incidence of alcohol and drug abuse, and use health care services to a greater extent [Belzer and…”
Lepola, U. M., Loft, H., & Reines, E. H. (2003) · International Clinical Psychopharmacology · doi:10.1097/01.yic.0000074988.54339.7c · Cited by 254
BELZER, K., & SCHNEIER, F. R. (2004) · Journal of Psychiatric Practice · doi:10.1097/00131746-200409000-00003 · Cited by 235
Lader, M., Stender, K., Bürger, V., & Nil, R. (2004) · Depression and Anxiety · doi:10.1002/da.20014 · Cited by 163 · cited 1×
“In a 24-week comparison with paroxetine, which has been used a reference drug for SAD in recent years, both drugs were superior to placebo, and at the end of the study, 20 mg/day escitalopram was superior to 20 mg/day paroxetine [Lader et al., 2004].”
Escitalopram continuation treatment prevents relapse of depressive episodes
Rapaport, M. H., Bose, A., & Zheng, H. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0107 · Cited by 121
Montgomery, S. A., Nil, R., Dürr-Pal, N., Loft, H., & Boulenger, J.-P. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n1009 · Cited by 115 · cited 2×
“, 2005] and a relapse prevention study [Montgomery et al., 2005].”
Is Interpersonal Psychotherapy Superior to Supportive Psychotherapy?
BROWN, W. A. (1996) · American Journal of Psychiatry · doi:10.1176/ajp.153.11.1509-a · Cited by 63
Cited by
Defining Response and Remission in Anxiety Disorders: Toward an Integrated Approach
Bandelow, B. (2006) · CNS Spectrums · doi:10.1017/s1092852900025815 · Cited by 52
Self-citationReliability and validity of the DSM-5 anxious distress specifier interview
Zimmerman, M., Clark, H., McGonigal, P., Harris, L., Holst, C. G., & Martin, J. (2017) · Comprehensive Psychiatry · doi:10.1016/j.comppsych.2017.02.010 · Cited by 45
Seo, H.-J., Song, H. R., Jeong, S., Kim, J.-B., Lee, M.-S., Kim, J.-M., Yim, H. W., & Jun, T.-Y. (2014) · Journal of Affective Disorders · doi:10.1016/j.jad.2013.09.037 · Cited by 13
“No universally accepted definition of anxious depression exists, although the HAM-D anxiety/somatization factor score was adopted in the STARD study and several other recent studies (Bandelow et al., 2007; Fava et al., 2008; Trivedi et al., 2008).”
Method
Metadata
- Authors
- Bandelow, B., Andersen, H. F., & Dolberg, O. T.
- Venue
- Depression and Anxiety
- Publisher
- Hindawi Limited
- Published
- 2006
- Volume
- 24
- Issue
- 1
- Pages
- 53-61
- ISSN
- 1091-4269 (ISSN-L)
- 1520-6394
- OpenAlex
- W2074489744
- Cited by
- 39
- References
- 9
- FWCI
- 1.13
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Escitalopram in the treatment of anxiety symptoms associated with depression. https://app.cochat.ai/papers/10.1002/da.20141
- The paper
- Bandelow, B., Andersen, H. F., & Dolberg, O. T. (2007). Escitalopram in the treatment of anxiety symptoms associated with depression. Depression and Anxiety. https://doi.org/10.1002/da.20141
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.